Mission and Focus

The NorLux Neuro-Oncology network is a joint network between the Luxembourg Institute of Health in Luxembourg and the Department of Biomedicine at the University of Bergen in Norway. The aim of this joint venture is to foster collaborative research, scientific competence building and staff exchange in the field of neuro-oncology.

The laboratories carries out basic and pre-clinical research with an emphasis in two major areas: 

1. understanding the biological mechanisms underlying the initiation and progression of malignant gliomas and,

2. identification of novel molecular targets for therapies against brain tumors. The ultimate goal of the laboratory is to improve current treatment options for patients with brain tumors.

NorLux will identify and validate novel mechanisms responsible for brain tumour initiation, growth and progression. Using unique patient-derived, pre-clinical animal model systems, combined with large-scale genomics and proteomics technologies, putative therapeutic targets will be identified. NorLux will create effective and tumor-selective therapeutic strategies that complement or substitute established therapies. The overall scientific and coordination objectives are to perform multidisciplinary research efforts of highest international stature within the field of brain tumour biology.